Oncology Central

What advances have been made in immune-therapy for renal cell carcinoma?


Renal cell carcinoma (RCC) is characterized by high immunogenicity, with a remarkable infiltration of immune cells, especially T cells, natural killer cells, dendritic cells and macrophages [1]. Before the advent of targeted therapy, cytokines including IL-2 and IFN-α were the standard of care in metastatic RCC (mRCC) treatment. Coppin et al. showed that IFN-α was associated with a small survival benefit (3.8 months) [2]. A retrospective analysis of seven Phase II trials testing high-dose IL-2 (HD IL-2) reported more durable responses in selected patients, with an objective response rate (ORR) of 14% including 5% of complete responses [3].

Restricted Content / Members Only

You cannot view this content because It is available to members only. Please or Register to view this area.




News Headlines

Leave A Comment

Please wait...

Would you like access to more immuno-oncology content?

Register with Oncology Central to find out the latest news, opinions and journal articles published in the oncology field by leading experts.